文献速递类风湿关节炎

类风湿关节炎患者长期持续使用利妥昔单抗的情况

Long-term persistence with rituximab in patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

4年后全队列60%仍在用药,停用最常见原因为无效(46%)和死亡(24%);停用者中46%换用其他生物制剂DMARD,托珠单抗最常见。

要点

  • 4年后全队列60%仍持续使用利妥昔单抗。
  • 停用利妥昔单抗最常见原因为无效(46%)和死亡(24%)。
  • 停用利妥昔单抗者中46%换用其他生物制剂DMARD,托珠单抗最常见。

核心结论

  • 这项大型研究纳入因重度类风湿关节炎开始利妥昔单抗治疗的患者,发现60%在4年后仍持续治疗。
  • 该研究还发现利妥昔单抗作为一线或二线生物制剂DMARD使用时耐受良好。

研究设计与样本

  • 研究为观察性队列,招募2008年至2011年间开始利妥昔单抗(MabThera)治疗的类风湿关节炎患者进入英国风湿病学会类风湿关节炎生物制剂登记。
  • 通过Kaplan-Meier估计起始后前4年的利妥昔单抗治疗持续时间,并查明停药原因,描述停药后后续生物制剂DMARD使用。

主要发现

  • 全队列60%在4年后仍使用利妥昔单抗。
  • 停用利妥昔单抗最常见原因为无效(46%)和死亡(24%)。
  • 在曾用过生物制剂DMARD的队列中,停用利妥昔单抗与类风湿因子(RF)阴性相关。
  • 停用利妥昔单抗者中46%开始使用另一种生物制剂DMARD,托珠单抗最常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the long term persistence of rituximab (RTX) in a large observational RA cohort, investigate persistence of RTX when used as a first or second line biologic DMARD (bDMARD), to characterize subsequent bDMARD treatment following RTX. METHODS: Patients with RA starting treatment with RTX (MabThera) between 2008 and 2011 were recruited into the British Society for Rheumatology Biologics Register for RA. Duration of RTX treatment over the first 4 years after initiation was estimated via Kaplan-Meier estimates and the reason for discontinuation was ascertained. Subsequent bDMARD use following RTX discontinuation was characterised. Treatment survival in bDMARD-naïve (first line RTX use) and experienced (second line RTX use) cohorts was described. RESULTS: One thousand six hundred and twenty-nine patients were recruited (1371 bDMARD-experienced and 258 bDMARD-naïve). Sixty percent of the whole cohort remained on RTX after 4 years. Ineffectiveness (46%) and death (24%) were the most common reason for RTX discontinuation. RTX discontinuation was associated with RF negativity for the bDMARD-experienced cohort. Of those that discontinued RTX, 46% initiated treatment with another bDMARD, with tocilizumab being the most common. CONCLUSION: This large study of patients initiating RTX treatment for severe RA found that 60% persisted with treatment after 4 years. This study also identified that RTX is tolerated well when used as a first or second line bDMARD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Oldroyd AGS, Symmons DPM, Sergeant JC, et al. Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018. PMID: 29566213. doi:10.1093/rheumatology/key036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。